European Innovation Council

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Patient-specific right heart pumps that free patients from heavy battery packages and increase patient's quality of life.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Quantune is a deep tech startup specializing in optics and photonics technology. The company develops a compact infrared spectrometer that miniaturizes traditional laboratory equipment for molecular analysis, making it accessible for both biomedical consumer devices and industrial applications. This innovative spectrometer facilitates continuous and non-invasive health monitoring, allowing clients to achieve real-time monitoring and analysis of chemical compounds and emissions. By transforming large-scale laboratory processes into a portable module, Quantune enables novel applications in various fields, enhancing the capabilities of health and environmental monitoring.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

Hideez is a cybersecurity company that specializes in manufacturing hardware and providing services for secure authentication. Based in the USA and Ukraine, the company offers the Hideez Key, a hybrid device combining wireless authentication, password management, and access control for both physical and digital environments. This multifunctional key uses encrypted Bluetooth, RFID, and NFC technologies, and supports various authentication standards, making it a versatile and secure solution for managing user credentials.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

King's College London (informally King's or KCL) is a public research university located in London, United Kingdom, and a constituent college of the federal University of London. King's is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. St Thomas' Hospital, which is now a teaching hospital of King's College London School of Medicine, has roots dating back to 1173. In 1836, King's became one of the two founding colleges of the University of London. King's is based in the centre of London and organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres for <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> , the most of any British university, and is a founding member of the King's Health Partners academic health sciences centre. King's has around 25,000 students and 6,113 staff and had a total income of £587 million in 2012/13, of which £164 million was from research grants and contracts. King's is a world-leading university, currently ranked 19th in the world (6th in the UK and 8th in Europe) in the 2013 QS World University Rankings, and 38th in the world (6th in the UK and 9th in Europe) in the 2013 Times Higher Education World University Rankings. There are currently 12 Nobel Prize laureates amongst King's alumni and current and former faculty. King's is a member of the Association of Commonwealth Universities, the European University Association, the Russell Group and Universities UK. It forms part of the 'golden triangle' of British universities.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

RespiQ is a healthtech startup that specializes in portable, non-invasive breath analysis technology aimed at the early detection and management of respiratory diseases. By utilizing advanced emission spectroscopy and artificial intelligence, RespiQ's device identifies volatile organic compounds (VOCs) in breath, enabling real-time detection of conditions such as COPD exacerbations. The company's focus on affordability, portability, and user-friendliness seeks to democratize access to advanced diagnostics, ultimately improving patient outcomes and reducing healthcare costs. In addition to respiratory diseases, RespiQ's versatile platform has potential applications for asthma, lung cancer, and infectious diseases. The company also offers an app that provides personalized health insights and dietary guidance, allowing users to monitor their health proactively. RespiQ's combination of technical and healthcare expertise positions it as a leader in breath diagnostics, with a commitment to enhancing overall health and well-being.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Ligence is a Deep Tech startup based in Lithuania, specializing in healthcare solutions developed by a team of medical doctors proficient in artificial intelligence. The company focuses on automating heart ultrasound image analysis through its flagship product, Ligence Heart. This technology employs deep learning algorithms to accurately recognize various heart image views and perform essential measurements automatically. By streamlining the analysis process, Ligence Heart allows physicians to bypass manual measurements, enabling cardiologists and sonographers to enhance efficiency and significantly reduce analysis time, thereby allowing them to concentrate more on patient care and treatment.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Rockfield Medical Devices is a small to medium-sized enterprise focused on transforming the enteral feeding market through innovative design and user-centered solutions. Founded by a team of experts in the medical device industry and research, the company aims to enhance the mobility and quality of life for individuals relying on tube feeding. Rockfield's platform introduces a lightweight and discreet mobile feeding system that significantly improves user experience while reducing technical support and maintenance costs for sales partners. Through its commitment to innovation and usability, Rockfield strives to deliver exemplary satisfaction to end users in the enteral feeding community.

Trisol Medical specializes in developing innovative medical devices for the treatment of tricuspid regurgitation. The company focuses on its transcatheter tricuspid replacement valve, which features a nitinol frame and specially designed leaflets aimed at effectively addressing tricuspid regurgitation while preserving the function of the right ventricle. Through its advanced technology, Trisol Medical offers comprehensive solutions for managing tricuspid regurgitation and right ventricle dysfunction, enhancing patient outcomes in the field of cardiac care.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Handiscover Sweden AB, founded in 2014 and based in Malmö, Sweden, operates an online booking platform focused on holiday accommodations for individuals with physical disabilities. This pioneering service features a unique classification system that allows users to filter options based on their specific mobility needs. Handiscover aims to simplify the process of finding accessible vacation rentals, catering to the diverse requirements of its users. Additionally, the platform assists companies and municipalities in gathering and presenting specialized accessibility data, ensuring that individuals with disabilities can easily discover and book suitable accommodations for their travels.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Cellbox Solutions is a technology company that specializes in innovative logistical solutions for the global BioMed industry. The company has developed a carbon dioxide incubator aimed at enhancing the storage, isolation, handling, and analysis of biological materials. This incubator supports the proper management of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the safe transport of living cells via roads, rails, or airways, Cellbox Solutions assists healthcare providers in their efforts to deliver advanced therapies and improve patient treatment outcomes.

Plasmacure is a Netherlands-based company that specializes in developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. Their patented solution effectively kills bacteria, stimulates cell proliferation, and enhances microcirculation, which helps reduce the risk of amputation. By addressing these critical aspects of wound healing, Plasmacure's technology aims to improve the quality of life for patients suffering from chronic wounds.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Scandinavian Real Heart is a medical technology company focused on developing an innovative artificial heart designed to assist patients awaiting heart transplants. Their Total Artificial Heart (TAH) closely mimics the natural pumping mechanics, pressure ratios, and pulse of a healthy heart, aiming to provide improved functionality compared to existing options in the market. This device serves primarily as a transitional solution for individuals on the transplant waiting list, with the potential to save lives by addressing the urgent need for effective cardiac support.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

Quantune is a deep tech startup specializing in optics and photonics technology. The company develops a compact infrared spectrometer that miniaturizes traditional laboratory equipment for molecular analysis, making it accessible for both biomedical consumer devices and industrial applications. This innovative spectrometer facilitates continuous and non-invasive health monitoring, allowing clients to achieve real-time monitoring and analysis of chemical compounds and emissions. By transforming large-scale laboratory processes into a portable module, Quantune enables novel applications in various fields, enhancing the capabilities of health and environmental monitoring.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Syntach is a medical device company focused on improving the care of individuals with heart failure through the development of a cardiac support device. This innovative device aims to restore the impaired movement of the mitral valve and provide natural support to the heart. Syntach offers a permanent, active implant that can be inserted using a minimally invasive technique, making it smaller than existing left ventricular assist devices (LVADs). This design not only enhances the quality of life for patients but also reduces the risk of complications, benefiting both men and women who require cardiac support.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

NC Biomatrix is focused on developing medical therapies aimed at restoring the natural biomechanics of the spine to address low back pain. The company offers a non-invasive treatment option that involves an injectable viscous gel designed to alleviate the underlying causes of lower back pain. By targeting the biomechanics of the spine, NC Biomatrix provides a novel solution for patients suffering from osteoarthritis and related conditions, improving their quality of life through effective pain management.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

AVATAR MEDICAL specializes in developing a virtual reality platform that creates 3D patient avatars from medical images. This innovative technology assists surgeons in visualizing complex medical data, evaluating surgical options, and enhancing training for medical fellows. By providing accurate and interactive representations of patients, the platform enables clinicians to better comprehend critical clinical information, ultimately improving the decision-making process in surgical planning. Additionally, AVATAR MEDICAL's approach fosters greater engagement with patients, allowing them to better understand their medical conditions and treatment options.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly focusing on MRI scanners. The company provides a cloud-based data analysis platform that ensures the calibration of images is traceable to standardized values. Its innovative cylindrical phantom design addresses the need for multiple sample vials during phantom preparation, allowing clinicians, medical physicists, and radiographers to obtain reproducible quantitative measurements of diseases across different patients, scanners, and clinics. This approach not only enhances the accuracy of MRI imaging but also holds the potential to reduce medical costs over time.

Axiles Bionics is a Brussels-based company that specializes in manufacturing robotic ankle-foot prostheses aimed at enhancing the quality of life for lower limb amputees. Founded in 2018 as a spin-off from Brubotics at the Free University of Brussels, the company focuses on developing advanced prosthetic technology that combines the strength and flexibility of a human ankle with robotic features. This innovative approach enables individuals with limb disorders to experience improved movement and support through the next generation of bionic feet. Axiles Bionics is dedicated to advancing assistive robotics to meet the needs of amputees effectively.

Arspectra is a medical technology firm that focuses on unique augmented reality solutions for the healthcare industry.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

FOx Biosystems is a biotechnology company improving biomolecular interaction analysis in life science research and industry. The company offers services in the development of custom applications e.g. custom probes, evaluation support, development of custom devices, and system support. It also enables the users to generate high-quality biomolecular data such as concentration measurements., affinity data, and kinetic data. FOx Biosystems aims to revolutionize the life sciences industry and research market using its real-time, label-free analysis technology. It was founded in 2017 by Filip Delport and Jeroen Lammertyn and is headquartered in Temse, Oost-Vlaanderen, Belgium.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

Gate2Brain is an early-stage biotech company dedicated to enhancing drug delivery across biological barriers, particularly the blood-brain barrier, through a patented peptide-based technology. This innovative platform aims to transport therapeutics directly to the brain, thereby improving the efficacy of treatments for neurological diseases and reducing associated side effects. Additionally, Gate2Brain focuses on developing therapeutics that can address rare pediatric cancers, positioning itself as a key player in advancing medical solutions for challenging conditions.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.